anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with active moderate-to-severe rheumatoid arthritis diagnosed according to the 2010 ACR criteria will be randomized to receive a blinded treatment course of either MabionCD20, EU-Rituximab (MabThera®) or US-Rituximab (Rituxan®) on the top of a stable methotrexate therapy. Two infusions of investigational drug at a dose of 1000 mg will be given at Day 1 and 15. Patients will be then followed for a minimum of 24 weeks to establish PK and therapeutic similarity and to compare PD, safety and immunogenicity parameters between the three rituximab products (Main Phase). Patients may receive a second course of investigational therapy at Week 24, provided that they meet re-treatment eligibility criteria specified in the study protocol. Subjects in MabionCD20 and EU-Rituximab groups will be continued on their assigned treatments, while all subjects in US-Rituximab group will be switched to MabionCD20. All subjects (re-treated and not re-treated) will continue the follow-up until Week 48 to collect long-term safety, immunogenicity and efficacy data.
Described herein are compositions and techniques related to the generation and therapeutic applications of artificial synapses. Artificial synapses are engineered extracellular vesicles comprising exosomes with a viscous binding agent incorporated on their surface to anchor a signaling domain to a biological target, such as a receptor. These engineered additives may be organized in a genetic vector construct expressed in mammalian cells, wherein the adhesive binding agent is attached to extracellular vesicles such as exosomes, presenting their associated signaling domains that are rapidly taken up by recipient cells. Artificial synapses exploit the hallmark biophysical and biochemical features of extracellular vesicles, allowing rapid deployment and scale-up. Importantly, such a strategy may allow for kinetically favorable signal generation and signal propagation. For example, this includes increasing the density of agonist presentation to support receptor clustering-a burdensome obstacle to traditional receptor targeting strategies.
The invention discloses a medicament for treating lymphoid tuberculosis and a preparation method thereof. The medicament comprises the following components in part by weight: 1 to 6 parts of kelp, 1 to 6 parts of seaweed, 1 to 6 parts of oyster shell, 1 to 6 parts of rhizoma smilacis glabrae, 1 to 6 parts of subprostrate sophora, 1 to 6 parts of wild buckwheat, 1 to 6 parts of perfoliate knotweed herb, 1 to 6 parts of bubble tree, 1 to 6 parts of nine rings, 1 to 6 parts of wild polygonum and 1 to 6 parts of citron day-lily. The medicament also comprises of wild buckwheat, schisandra propinqua leaf,chaulmoogratree, perfoliate knotweed herb, radix aconite and kusnezoff monkshood, and semen momordicae. The medicament is prepared by the following steps of: A, respectively taking 1 part of kelp, seaweed, oyster shell, rhizoma smilacis glabrae, subprostrate sophora, wild buckwheat, perfoliate knotweed herb, bubble tree, nine rings, wild polygonum and citron day-lily, and cutting into segments respectively; B, decocting the segments in a container for three times and merging into 60 milliliters of 100 percent decoction; C, taking the wild buckwheat and schisandra propinqua leaf and grinding into powder; and D, putting the ground powdery medicaments into the container, and adding warm boiled water, stirring uniformly and sealing. The medicament is used in a way that the finished liquid medicine is orally taken in three days; meanwhile, the pasty finished medicament is externally applied to the wound. The Chinese herbal medicament can effectively and radically cure the lymphoid tuberculosis disease.
The active ingredient in the proton pump inhibitor esomeprazole magnesium delayed-release capsules USP for oral administration is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole-1-yl) magnesium dihydrate. Esomeprazole is the S-isomer of omeprazole, which is a mixture of the S- and R- isomers. (Initial U.S. approval of esomeprazole magnesium: 2001). Its molecular formula is (C17H18N3O3S)2 Mg x 2 H2O with molecular weight of 749.15 as a dihydrate and 713.12 on an anhydrous basis. The structural formula is:

The magnesium salt is a white to slightly colored powder. It contains 2 moles of water of solvation and is practically insoluble in water. The stability of esomeprazole magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25°C and about 8 hours at 37°C.

Esomeprazole magnesium is supplied in delayed-release capsules. Each delayed-release capsule contains 20 mg, or 40 mg of esomeprazole (present as 21.75 mg, or 43.5 mg esomeprazole magnesium dihydrate USP) in the form of enteric-coated granules with the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, magnesium carbonate, magnesium oxide, methacrylic acid and ethyl acrylate copolymer dispersion, mono and di glycerides, polysorbate 80, sugar spheres (which contains liquid glucose, starch (maize) and sucrose), talc, titanium dioxide, and triethyl citrate. In addition, the empty hard gelatin capsule shells contain gelatin and sodium lauryl sulfate. The capsule shells are imprinted with edible ink containing butyl alcohol, dehydrated alcohol, isopropyl alcohol, propylene glycol, shellac, strong ammonia solution and yellow iron oxide.   
  
Meets USP Dissolution Test 2.
Myoclonic-tonic (MT) and spasm-tonic (ST) seizures represent distinctive features in late infantile epileptic encephalopathy (LIEE). This commentary aims to delineate the electroclinical characteristics of MT and ST seizures, setting them apart from other seizure types. Our analysis encompasses 211 ST and MT seizures observed in 31 patients diagnosed with LIEE, providing a comprehensive overview of video-EEG features and polygraphic signatures. In MT seizures, EEG findings reveal a high-voltage diffuse spike/polyspike and wave discharge, often succeeded by diffuse electrodecrements. The amplitude-integrated EEG (aEEG) signature is described as a "reversed checkmark." Conversely, ST seizures exhibit EEG findings such as a vertex positive deflection after a slow-wave and relative electrodecrement, with intermixed epileptiform discharges. In comparison to MT seizures, polygraphic characteristics in ST seizures appear more distinct, featuring a brief rhomboid shape corresponding to the spasm, followed by a lengthier rectangular shape indicative of the tonic phase of the ST seizure. While the pathophysiology of ST and MT seizures remains inadequately understood, their concurrent occurrence and association with other seizure types (tonic, epileptic spasm, myoclonic) within the temporal context of LIEE and other epileptic encephalopathies prompt us to anticipate advancements in our understanding through future research. We hope that this study serves as a foundation for unraveling these complexities in the times to come.
Potential participants will be identified from the follow-up cohort of chronic hepatitis B in the third Affiliated Hospital of Sun Yat-sen University (3rd SYSU). The hepatologists at the 3rd SYSU's Infectious Disease Institute will ask each potential participant if she/he is interested in participating. If the patient expresses an interest in the study, one of the researchers will meet with the patient when he/she is at the 3rd SYSU for a regular appointment and will describe the study to the potential participant. If a patient continues to be interested in participating, she/he will be given a copy of the review board approved consent document to read. The consent document will be used as a guide for explaining the study in detail to the patient. The participant allocated to the experimental group will be contacted by one of the investigators on the research team and instructed to begin taking 2 tablets per day (800 IU total) of vitamin D3 besides their regular anti-virus treatment. Those patients allocated in the control group will be informed that they are not to take any vitamin D3 and they will be followed as controls for this study. The researcher will investigate general treatment benefits and the potential to reduce the development of Hepatocellular carcinoma (HCC), also known as liver cancer. Improvement of treatment benefits will be determined by interviews with patients, the level of HBsAg and HBeAg, the development of liver fibrosis and evidence of HCC on routine imaging.
Single dose administration of PF-06954522 and placebo. Participants will receive up to 4 dose levels of PF-06954522 and up to 2 dose levels of matching placebo.
Compounds of formula (I), wherein R represents a C1-12? straight-chain alkyl radical which may comprise one or more halogen atoms; a C3-12? branched-chain alkyl radical which may comprise one or more halogen atoms; a C2-8? alkenyl radical; or a C1-4? alkyl radical comprising an aromatic core; R' represents a hydrogen atom or an alkoxycarbonyl grouping of formula (a); wherein R1? represents a C1-6? alkyl radical; and X represents an oxygen atom or a (b) grouping; the cosmetically or pharmaceutically acceptable acid addition salts thereof, and the use thereof for treating hair loss.
No specific information is available on the treatment of overdosage with VASERETIC. Treatment is symptomatic and supportive. Therapy with VASERETIC should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage, and correction of dehydration, electrolyte imbalance and hypotension by established procedures.

Enalapril Maleate – Single oral doses of enalapril above 1,000 mg/kg and ≥ 1,775 mg/kg were associated with lethality in mice and rats, respectively. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure).

Hydrochlorothiazide – Lethality was not observed after administration of an oral dose of 10 g/kg to mice and rats. The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
BACKGROUND: Patient-rated motor symptoms (PRMS) and clinician-rated motor symptoms (CRMS) often differ in Parkinson's disease (PD).
OBJECTIVE: Our goal was to investigate the determinants and clinical implications of PRMS compared with CRMS in PD.
METHODS: This retrospective, observational cohort study analyzed the cross-sectional associations and longitudinal impacts of PRMS as assessed by the Movement Disorders Society-sponsored Unified PD Rating Scale (MDS-UPDRS) part 2, while controlling for CRMS measured by MDS-UPDRS part 3. Longitudinal analyses used Cox proportional hazards models and multiple linear mixed-effects random intercepts/slope models, adjusting for many clinical predictors. We conducted propensity score matching (PSM) to reinforce our analyses' robustness and surface-based morphometry to investigate neural correlates.
RESULTS: We enrolled 442 patients with early-stage PD. At baseline, regardless of CRMS, PRMS were associated with the severity of postural instability and gait disturbance (PIGD). Notably, PRMS independently and more accurately predicted faster long-term deterioration in motor function than CRMS (Hoehn and Yahr 4, adjusted hazard ratio per +1 point = 1.19 [95% confidence intervals, 1.08-1.32]), particularly in PIGD (PIGD subscore, β-interaction = 0.052 [95% confidence intervals, 0.018-0.086]). PSM confirmed these findings' robustness. Surface-based morphometry suggested that enhanced sensory processing was distinctively associated with PRMS.
CONCLUSIONS: In early-stage PD, PRMS weighed different aspects of symptoms and more effectively predicted motor deterioration compared to CRMS, with distinctive brain structural characteristics. The superior sensitivity of PRMS to subtle declines in drug-refractory symptoms like PIGD likely underlie our results, highlighting the importance of understanding the differential clinical implications of PRMS to prevent long-term motor deterioration. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Large ventral hernias require complex surgical techniques, such as component separation. We are presenting a case of an incisional hernia measuring 15×8 cm. The hernia was covered with an overlying thin layer of skin and hernia sac. The skin of this layer was densely adherent to the underlying hernial sac. Because of the thin hernial sac and adherent nature of the skin, approximately 3 cm of the hernial sac was preserved. We used this hernial sac as the anterior sheath 'extension' for a tension-free closure. Posterior component separation with transverse abdominis muscle release was done to close the posterior layer without tension and to place a 23×16 cm mesh in the retrorectus plane. By using the hernial sac in repair, we avoided anterior component separation and achieved tension-free closure of the anterior layer.
Systems and techniques for extracting information-containing payloads from DNA or other polynucleotides are provided. Decoding the sequence of payload regions from multiple polynucleotides to obtain encoded information includes sequencing the molecules with a polynucleotide sequencer. Reads generated by the polynucleotide sequencer can include information from multiple different sources mixed together. Primer sequences present in the reads identify which reads contain information from the same source. A computationally efficient technique for finding primer sequences in the reads includes comparing hashes of the reads and hashes of primer sequences to find an approximate location then computing edit distances between the primer sequences and the reads to find an exact location. Reads that include the same primer sequences may be clustered together. Sequences of the payload regions are extracted based on the locations of the primer sequences.
PROBLEM TO BE SOLVED: To provide a system for controlling drug release which realizes appropriate control of rate and duration of drug release and which can be used, without limitations to types of drugs, in retina or vitreous. SOLUTION: This system for controlling drug release is composed of a nanosphere which comprises nano-size particles. The particles are made of a synthetic biodegradable polymer and contain drugs uniformly. Using the system, efficient delivery of drugs to retina or vitreous, as target sites is realized. The synthetic biodegradable polymer is preferably a polylactic acid or a lactic acid-glycolic acid copolymer. The drugs are contained in the particles preferably as a matrix. The average particle diameter of the nanosphere is preferably from 50 to 200 nm.
This is the control arm. The TEVAR or TAVI device will be flushed with at least 60mL of standard saline to reduce bubbles in the reservoir prior to deployment. This is the standard of care.
For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
The invention discloses a hair loss preventing plant extract, which is prepared from raw materials including dried ginger, astragalus root and sour fruit. The invention adopts plant raw materials with specific types and specific proportions and is matched with a proper preparation method, so that the extract can effectively improve alopecia. The invention also discloses a preparation method and application of the plant extract. The plant extract can promote the autophagy of the hair papilla cells, enhance the activity of the hair papilla cells and has very obvious effect of promoting the hair papilla cells to express Vascular Endothelial Growth Factor (VEGF). VEGF can stimulate and maintain the formation and function of capillary vessels around hair follicles, provide more nutrition for hair papilla cells, and delay the aging of the hair papilla cells, thereby realizing the anti-alopecia effect. The anti-hair loss plant extract has the advantages of simple extraction steps, easy operation, obvious anti-hair loss effect, safe and nontoxic formula and no side effect.
Nefopam is a centrally-acting anti-nociceptive compound with supraspinal and spinal sites of action. It inhibits monoamine reuptake, modulates descending serotoninergic pain, and may also interact with a dopaminergic pathway. Because its mechanism of action is distinct from that of other analgesic opioids, nefopam may well have a role in analgesic protocols. The role of nefopam in multimodal analgesia has been extensively investigated in laparoscopic cholecystectomy. However, there is general agreement that more studies are needed to determine the ideal multimodal strategy. No previous study has investigated a combination regimen of the three most commonly prescribed non-opioid analgesics (NOA) (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy.

The aim of our study is to compare a combination regimen of three NOA (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy. We will try to demonstrate the benefit with the addition of a third NOA, which is the nefopam, to the double-drug regimen including ketoprofen and paracetamol. Our hypothesis is that this combination regimen of three NOA is associated with less postoperative pain, less opioid consumption, shorter length of post-anesthesia care unit (PACU) stay, and fewer opioid-related adverse effects and postoperative complications compared to the double-drug regimen of ketoprofen and paracetamol.

In this prospective randomized double-blind study, 90 patients aged 18 to 64 years, with American Society of Anesthesiologists (ASA) physical status I and II, will be randomly assigned using a computer-generated random number table to one of two treatment groups. Group A will receive sevoflurane-dexmedetomidine based anesthesia with ketoprofen and paracetamol for postoperative pain control, and group B will receive sevoflurane-dexmedetomidine based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control. The primary outcome measure of this study is total morphine consumption in PACU. Normally distributed data will be summarized as mean ± SD and non-normally distributed data will be summarized as median \[interquartile range\]. This study would have an impact on our current practice and may help find out the best multimodal analgesic strategy to control postoperative pain after laparoscopic cholecystectomy.
A method of making sodium zirconium carbonate is described which involves forming a mixture of zirconium oxychloride with soda ash and then heating at a sufficient teperature and for a sufficient time to form the sodium zirconium carbonate. Subsequent washing and filtration steps can further form parts of the process. A novel sodium zirconium carbonate is further described which contains from about 2 wt% to about 5wt% Na+; from about 44 wt% to about 50 wt% ZrO2; from about 12 wt% to about 18 wt% CO32; and from about 30 wt% to about 40 wt% H2O or LOD. Methods fo making zirconium basic carbonate are further described which involve titrating an aqueous slurry of sodium zirconium carbonate to a pH of from about 3.5 to about 4.0 with an acidic agent wherin the sodium zirconium carbonate has a moisture content of form about 15% to about 25% LOD is solid form. The process further involves washing the aqueous slurry containing the formed zirconium basic carbonate with water. A novel zirconium basic carbonate is further disclosed which has a minimum adsorption capacity of from about 30 to about 35 mg/PO4-P/gm SZC; a minimum HCO3- content of from about 2 to about 4 mEq HCO3-gm/SZC; a leachable Na+ content of from about 1.5 to about 2.0 mEq Na+/gm SZC; and/or a pH range of titrated sodium zirconium carbonate of from about 6 to about 7. A methof of making zirconium phosphate is also disclosed which involves treating sodium zirconium carbonate with caustic soda to from an alkaline hydrous zirconium oxide which is subsequently heated and mixed with phosphoric acid to obtain an acid zirconium phosphate which can be titrated with caustic soda to achieve the desired zirconium phosphate. Novel zirconium phosphates are also disclosed as well as uses for the above zirconium containing materials.
Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
Computer program products, methods, systems, apparatus, and computing entities for extracting lab result data from lab reports are provided. In one example embodiment, an example computing device receives a lab report. The computing device identifies one or more relevant portions of the lab report. The computing device then generates parsed lab report data from only the identified one or more relevant portions of the lab report. Subsequently, the computing device extracts patient information and lab results from the parsed lab report data. Using various embodiments of the present invention, patient information and lab results can be efficiently extracted for incorporation into structured data sets maintained, for example, by a healthcare company.
An oral vaccine composition against enterotoxigenic E. coli caused diarrhea in humans is disclosed. It comprises a defined amount of at least 100 mu g of at least three different types of colonization factor antigens (CFAs), e.g. 100 to 300 mu g of each type, selected from the group consisting of CFA I, CFA II (CS1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6), on killed E. coli bacteria lacking the gene encoding the heat labile enterotoxin (LT - ), together with a defined amount of the B-subunit of cholera toxin (CTB), e.g. 0.5-2.0 mg, and a vehicle, such as PBS, which vaccine composition is purified from possible heat stable enterotoxin (ST). Such vaccines are useful in the prevention of enterotoxigenic E. coli caused diarrhea in humans such as that experienced whilst traveling. (62) Divided out of 512014